BS001 (OH2) injection for the treatment of recurrent central nervous system tumors clinical trials launched in Beijing Tiantan Hospital

:admin  :2021-08-05 19:01:34  :

It was officially started in Beijing Tiantan Hospital, Capital Medical University on August 3, 2021 of the single-arm, open, multi-center clinical trial to study the safety, tolerability and preliminary efficacy of the oncolytic virus drug candidate BS001 from Binhui Bio for the patients recurrent from the surgery of central nervous system tumors.